How We Source

Transparency matters. You deserve to know not just what you're buying, but where it comes from, who handles it, and how we verify it before it leaves our facility.

Where our raw materials come from

Industry data consistently shows that the overwhelming majority of active pharmaceutical ingredients used in Europe and North America are produced overseas. Most peptide suppliers rely on the same overseas synthesis facilities — and many that claim local manufacture simply cannot document it.

We're upfront about it: our raw APIs come from established synthesis partners in Asia operating to documented quality systems. That partnership is deliberate — these facilities specialise in solid-phase peptide synthesis at the purity grades research demands.

Finished in the UK — every batch, every step

All finishing, formulation, vialing, packaging and dispatch take place at our UK facility under hands-on oversight from our team. Lyophilisation, sterile filtration and final inspection are all completed locally before any vial enters inventory.

When you receive a Synova vial, it has been finished, labelled and quality-checked on home soil — not drop-shipped from a warehouse with no chain of custody.

Independent third-party testing

Every batch is sampled and submitted to Brown Biology, an independent analytical laboratory, for identity confirmation by mass spectrometry and purity assessment by HPLC.

We only release lots that exceed a minimum 98% purity threshold — the vast majority sit above 99%. Failed lots are rejected and never enter inventory. The accompanying Certificate of Analysis travels with the product through pick, pack and dispatch, and is available on our COA page.

Why this matters

Research is only as reliable as the materials behind it. A short, documented sourcing chain — overseas synthesis from qualified partners, finished and tested in the UK — is what allows you to trust the vial sitting on the bench.